Sindrome.del.Ovario.Poliquistico

Inducción a la ovulación 145
ovarian syndrome. Fertil Steril. 1991;55:
56-60.
59
Balasch J, Fabregues F, Casamitjana R,
Penarrubia J, Vanrell JA. A pharmacokinetic
and endocrine comparison
of recombinant follicle-stimulating hormone
and human menopausal gonadotrophin
in polycystic ovary syndrome.
Reprod Biomed Online. 2003;6:296-301.
60
Coelingh Bennink HJT, Fauser B, Out
HJ. Recombinant follicle-stimulating
hormone (FSH; Puregon) is more efficient
than urinary FSH (Metrodin) in
women with clomiphene citrate-resistant,
normagonadotropic, chronic anovulation:
a prospective, multicenter,
assessor-blind, randomized, clinical trial.
Fertil Steril. 1998;69:19-25.
61
Hughes E, Collins J, Vandekerckhove
P. Ovulation induction with urinary
follicle stimulating hormone versus
human menopausal gonadotropin for
clomiphene-resistant polycystic ovary
syndrome. Cochrane Database Syst Rev.
2000;(2):CD000087. Review.
62
Bayram N, Van Wely M, Van Der Veen
F. Recombinant FSH versus urinary
gonadotrophins or recombinant FSH for
ovulation induction in subfertility associated
with polycystic ovary syndrome.
Cochrane Database Syst Rev. 2001;(2):
CD002121. Review.
63
Fleming R, Haxton MJ, Hamilton MPR,
McCune GS, Black WP, MacNaughton
MC, et al. Successful treatment of infertile
women with oligomenorrhoea using
a combination of a LHRH agonist and
exogenous gonadotrophins. Br J Obstet.
1985;92:369-73.
64
Homburg R, Levy T, Berkovitz D,
Farhi J, Feldberg D, Ashkenazi J, et
al. Gonadotropin-releasing hormone
agonist reduces the miscarriage rate for
pregnancies achieved in women with
polycycstic ovary syndrome. Fertil Steril.
1993;59:527-31.
65
Homgurg R, Eshel A, Kilborn J, Adams
J, Jacobs HS. Combined luteinising
hormone-releasing hormone analogue
and exogenous gonadotrophins for the
treatment of infertility associated with
polycystic ovary syndrome. Human
Reprod. 1990;5:32-5.
66
Hughes E, Collins J, Vandekerckhove
P. Gonadotrophin-releasing hormone
analogue as an adjunct to gonadotropin
therapy for clomiphene-resistant
polycystic ovarian syndrome. Cochrane
Database Syst Rev. 2000;(2):CD000097.
Review.
67
Elkind-Hirsch KE, Webster BW, Brown
CP, Vernon MW. Concurrent ganirelix
and follitropin beta therapy is an effective
and safe regimen for ovulation
induction in women with polycystic
ovary syndrome. Fertil Steril. 2003;79:
603-7.
68
Cardone VS. GnRH antagonists for treatment
of polycystic ovarian syndrome.
Fertil Steril. 2003;80 Suppl 1:S25-1.
69
Hillier SG. Current concepts of the roles
of follicle stimulating hormone and
luteinizing hormone in folliculogenesis.
Human Reprod. 1994;9:188-91.
70
Loumaye E, Engrand P, Shoham Z,
Hillier SG, Baird DT. Clinical evidence
for an LH «ceiling» effect induced by
administration of recombinant human
LH during the late follicular phase
of stimulated cycles in World Health
Organization type I and type II anovulation.
Hum Reprod. 2003;18:314-22.
71
Hughes JN, Soussis J, Calderon I,
Balasch J, Anderson RA, Romeu A. On
behalf of the Recombinant LH Study
Group. Does the addition of recombinant
LH in WHO group II anovulatory
women over-responding to FSH treatment
reduce the number of developing
follicles? A dose-finding study. Hum
Reprod. 2005;20:629-35.
72
Hamilton-Fairy D, Kiddy D, Watson H,
Paterson C, Franks S. Association of
moderate obesity with a poor pregnancy
outcome in women with polycystic
ovary syndrome treated with low dose
gonadotrophin. Br J Obstet Gynaeol.
1992;99:128-31.